+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 182 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are evaluating the combination of BNT324, a B7-H3 antibody-drug conjugate, with BNT327, a bispecific antibody targeting PD-L1 and VEGF, in adults with advanced or metastatic small cell lung cancer SCLC and non-small cell lung cancer NSCLC. This two-part Phase IbII trial aims to find safe dose levels, optimize dosing, and assess preliminary efficacy and safety in various lung cancer patient groups. Participants in Part 1 receive escalating doses of BNT324 with BNT327 to determine recommended dose levels. Part 2 compares these dose levels in randomized cohorts of treatment-naive NSCLC and relapsed SCLC patients, with additional cohorts receiving the optimal dose to further evaluate efficacy and safety. Treatments are given via intravenous infusion, and dosing is adjusted based on safety and response data. Throughout the study, participants undergo screening, treatment, safety follow-up, and long-term survival monitoring. Researchers assess dose-limiting toxicities, adverse events, objective response rates, disease control, progression-free survival, and overall survival. Treatment effects are evaluated up to 87 months, with close monitoring for side effects and treatment tolerability during and after therapy.

Age: 18Years +All GendersPhase 1Phase 2
91 locations
S

Actively Recruiting

Researchers are evaluating the effects of Diaberine, a berberine-based nutraceutical, on blood sugar regulation and metabolism in adults with metabolism disorder. This randomized, triple-blind, placebo-controlled trial will study 80 participants aged 18 to 70 over 24 weeks to assess how well this dietary supplement may aid in these health areas. Participants will be randomly assigned to one of two groups. One group will take Diaberine capsules containing Vitamin B12, berberine, magnesium citrate, cinnamon bark extract, chromium, and other ingredients three times daily, 15 minutes before meals. The other group will take placebo capsules with similar appearance but without the active ingredients. Both treatments will continue for 24 weeks with regular monitoring. During the study, participants will have their blood sugar regulation and metabolism measured at baseline, week 12, and week 24. Additionally, quality of life and weight changes will be tracked at multiple points throughout the 24 weeks. Participants will be monitored through questionnaires, blood tests, and weight assessments to evaluate the supplements effects and tolerance over time.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.

Age: 18Years +All GendersPhase 1Phase 2
114 locations
E

Actively Recruiting

Researchers are conducting a Phase 1, first in human, open-label trial to evaluate ALX2004, an antibody drug conjugate targeting EGFR, in participants with advanced or metastatic selected solid tumors. The study focuses on patients with non-small cell lung cancer NSCLC, head and neck squamous cell carcinoma HNSCC, esophageal squamous cell carcinoma ESCC, and colorectal cancer CRC who have received prior treatments. This research aims to assess the safety, dosing, and effectiveness of ALX2004 in these advanced cancers. The study includes three phases Phase 1a dose escalation to find safe dose levels, dose exploration to refine dosing in specific tumor types, and Phase 1b dose expansion where participants receive the recommended phase 2 dose. ALX2004 is administered by intravenous infusion. Participants will be enrolled sequentially into escalating dose levels initially, followed by enrollment into selected dose levels for further evaluation. Participants will undergo assessments for dose limiting toxicities, adverse events, and tumor response using RECIST criteria up to two years after dosing. Pharmacokinetics including drug concentration and clearance will be measured along with immunogenicity and survival outcomes. The study involves monitoring safety and treatment effects over time, with expected enrollment of up to 170 patients and a study duration extending to late 2027.

Age: 18Years +All GendersPhase 1
12 locations
P

Actively Recruiting

Researchers are studying MEN2312, a lysine acetyltransferase 6 KAT6 inhibitor, in adults with advanced breast cancer that is not curable. This first-in-human, phase 1 study evaluates MEN2312 alone and in combination with elacestrant to understand its safety and determine the best dose. Participants have specific genetic alterations in their tumors and have received prior endocrine therapy and cyclin-dependent kinase 4 and 6 inhibitor treatment. Participants will be randomly assigned to receive either MEN2312 by itself or MEN2312 combined with elacestrant, both given as oral tablets. The study follows a sequential design and aims to identify dose-limiting toxicities and recommend the phase 2 dose over several months of treatment. This includes monitoring drug levels in the body and how the body processes the medications. During the study, participants will have regular assessments to monitor side effects, tumor response, and overall health. These include evaluating the number of dose-limiting toxicities within the first 28 days and tracking response rates, progression-free survival, and overall survival for up to nine months after treatment ends. Researchers will also measure drug concentration and excretion to better understand the treatment effects and safety over time.

Age: 18Years +All GendersPhase 1
45 locations
E

Actively Recruiting

Researchers are evaluating YL217, an antibody-drug conjugate targeting the CDH17 protein, in patients with advanced solid tumors. This first-in-human Phase 1 study aims to assess the safety, tolerability, pharmacokinetics, and effectiveness of YL217. The study focuses on gastrointestinal cancers, addressing a significant unmet medical need by building on preclinical results that showed tumor growth suppression in animal models. Participants will receive YL217 either alone or in combination with bevacizumab, with or without 5-fluorouracil and leucovorin. YL217 is given through intravenous infusion, and bevacizumab and 5-FULV are also administered via intravenous infusion on a biweekly schedule. The study follows a sequential design with dose escalation, backfill, and expansion phases for both combination and monotherapy groups. During the study, participants will undergo regular monitoring for side effects and dose-limiting toxicities over approximately three years. Assessments include measuring tumor response, pharmacokinetics, immunogenicity, and performance status. Safety evaluations involve tracking adverse events, oxygen saturation, and other clinical parameters. This comprehensive approach will help researchers understand how YL217 behaves in the body and its potential impact on advanced solid tumors.

Age: 18Years +All GendersPhase 1
21 locations
P

Actively Recruiting

Researchers are studying casdatifan, alone and in combination with other drugs, in people with advanced solid tumors and clear cell renal cell carcinoma ccRCC. This Phase 1 trial aims to evaluate the safety, tolerability, and how the body processes casdatifan. The study includes two parts a dose escalation stage for advanced solid tumors and ccRCC, and a dose expansion stage focusing on ccRCC with different drug combinations. Participants receive casdatifan orally, either once or twice daily, depending on their assigned group. Some groups also receive casdatifan combined with cabozantinib or infusions of zimberelimab with or without ipilimumab. The study involves different cohorts for dose escalation and dose expansion, each exploring various dosing regimens and combinations. During the study, participants are closely monitored for side effects and dose-limiting toxicities over up to four months. Researchers assess tumor response using standard criteria and measure drug levels in the blood to understand pharmacokinetics. Safety is tracked through adverse event reporting, and participants attend regular visits for evaluations throughout the study period.

Age: 18Years +All GendersPhase 1
25 locations
P

Actively Recruiting

Researchers are evaluating CPO301, an antibody drug conjugate, in adults with advanced or metastatic solid tumors who have progressed on prior treatments or are ineligible for standard therapy. This Phase 1 trial aims to assess the safety, tolerability, and optimal dosing of CPO301, as well as its pharmacokinetics, immunogenicity, and preliminary effectiveness, including its relationship to EGFR biomarker mutations. The study is sponsored by Conjupro Biotherapeutics, Inc. The trial has two parts. In Part A, patients receive escalating doses of CPO301 by intravenous injection every three weeks to identify the maximum tolerated dose or recommended phase 2 dose. In Part B, additional patients receive CPO301 at the dose determined safe and tolerable in Part A, focusing on those with non-small cell lung cancer with EGFR mutations and other tumor types. Treatment cycles last 21 days, and dose adjustments may be made based on safety assessments. Participants will provide informed consent, undergo screening to confirm eligibility, and attend study visits to receive CPO301 every three weeks until the study doctor decides to stop treatment. Researchers will monitor participants for disease progression every three months for up to two years. Safety, drug metabolism, immune response, and preliminary antitumor activity will be evaluated throughout the study, which is expected to last about one year for the primary outcomes.

Age: 18Years +All GendersPhase 1
14 locations
P

Actively Recruiting

Researchers are investigating the drug OKN4395, alone and combined with pembrolizumab, in adults with advanced solid tumors. This Phase 1 study aims to assess the safety, tolerability, blood levels, and anti-tumor activity of OKN4395 both as a single treatment and alongside pembrolizumab. The study focuses on tumors with a COX2-associated immunosuppressive pathway and includes multiple cancer types such as sarcoma, non-small cell lung cancer, colorectal cancer, and gastric cancer. The study is divided into two main parts. Part 1a includes dose escalation of OKN4395 alone or with pembrolizumab every 21 days, increasing doses based on safety evaluations, and a substudy testing how food and stomach acid affect OKN4395 blood levels. Part 1b evaluates OKN4395 alone or combined with pembrolizumab in four cancer cohorts. Participants receive oral OKN4395 twice daily, with pembrolizumab given intravenously every three weeks where applicable. The substudy involves dosing under fasting, fed, and high stomach pH conditions using famotidine. Participants will be monitored through regular visits lasting up to 27 months for Part 1a and up to 12 months for Part 1b. Assessments include safety checks for side effects, blood tests for drug levels and lab abnormalities, ECGs, tumor measurements, and evaluation of treatment response and progression. The study tracks dose adjustments, adverse events, and survival outcomes to understand the drugs effects and tolerability in solid tumor patients.

Age: 18Years +All GendersPhase 1
10 locations

1-10 of 182

1